Mustang Bio Files S-1 with SEC
Ticker: MBIO · Form: S-1 · Filed: Jan 15, 2025 · CIK: 1680048
Sentiment: neutral
Topics: sec-filing, s-1, biotech
TL;DR
Mustang Bio dropped an S-1, check financials and future plans.
AI Summary
Mustang Bio, Inc. filed an S-1 form on January 15, 2025, detailing its financial status and offering information. The company, incorporated in Delaware with its principal office in Worcester, MA, is involved in the pharmaceutical preparations industry. The filing includes details on various financial metrics and past transactions, such as a registered direct offering in June 2024 and a securities purchase agreement in October 2023.
Why It Matters
This S-1 filing provides crucial insights into Mustang Bio's financial health and strategic plans, which could impact investors and the biotechnology sector.
Risk Assessment
Risk Level: medium — S-1 filings often indicate a company is seeking to raise capital or undergo significant corporate changes, which inherently carries risk.
Key Numbers
- 8604104 — Financial Metric (Appears in financial data section of the filing)
- 7684508 — Financial Metric (Appears in financial data section of the filing)
- 8374869 — Financial Metric (Appears in financial data section of the filing)
- 7100111 — Financial Metric (Appears in financial data section of the filing)
Key Players & Entities
- Mustang Bio, Inc. (company) — Filer of the S-1 document
- 0001410578-25-000028 (dollar_amount) — Accession Number for the filing
- 20250115 (dollar_amount) — Filing date
- Worcester, MA (company) — Location of Mustang Bio's business and mailing address
- Fortress Biotech Inc. (company) — Mentioned in relation to past transactions
- 2024-06-19 (dollar_amount) — Date of a registered direct offering
- 2023-10-26 (dollar_amount) — Date of a securities purchase agreement
FAQ
What is the primary purpose of this S-1 filing for Mustang Bio, Inc.?
The S-1 filing is typically used by companies to register securities for public sale, indicating potential capital raising or significant corporate actions.
When was Mustang Bio, Inc. incorporated and where is its principal executive office located?
Mustang Bio, Inc. was incorporated in Delaware and its principal executive office is located at 377 Plantation Street, Worcester, MA 01605.
What industry does Mustang Bio, Inc. operate in?
Mustang Bio, Inc. operates in the Pharmaceutical Preparations industry, with SIC code 2834.
What significant past transactions are mentioned in the filing data?
The filing data mentions a registered direct offering on June 19, 2024, and a securities purchase agreement on October 26, 2023.
What is the filing date and accession number for this S-1 submission?
The filing date is January 15, 2025, and the accession number is 0001410578-25-000028.
Filing Stats: 4,654 words · 19 min read · ~16 pages · Grade level 15.6 · Accepted 2025-01-15 16:17:13
Key Financial Figures
- $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underly
- $0.0001 — of common stock at an exercise price of $0.0001 per share. Each pre-funded warrant is b
- $0.1438 — stock on the Nasdaq Capital Market was $0.1438 per share. The combined offering price
- $25,000 — n-accountable expenses in the amount of $25,000 and for its legal fees and expenses and
- $100,000 — t-of-pocket expenses in an amount up to $100,000, up to $3,500 for road show expenses, a
- $3,500 — nses in an amount up to $100,000, up to $3,500 for road show expenses, and for its cle
- $15,950 — its clearing expenses in the amount of $15,950. In addition, we have agreed to issue t
Filing Documents
- tmb-20240930xs1.htm (S-1) — 4631KB
- tmb-20240930xex23d1.htm (EX-23.1) — 5KB
- tmb-20240930xexfees.htm (EX-FILING FEES) — 66KB
- tmb-20240930xs1001.jpg (GRAPHIC) — 6KB
- tmb-20240930xex23d1001.jpg (GRAPHIC) — 3KB
- tmb-20240930xex23d1002.jpg (GRAPHIC) — 4KB
- 0001410578-25-000028.txt ( ) — 17009KB
- tmb-20240930.xsd (EX-101.SCH) — 104KB
- tmb-20240930_cal.xml (EX-101.CAL) — 72KB
- tmb-20240930_def.xml (EX-101.DEF) — 612KB
- tmb-20240930_lab.xml (EX-101.LAB) — 558KB
- tmb-20240930_pre.xml (EX-101.PRE) — 883KB
- tmb-20240930xs1_htm.xml (XML) — 2273KB
Risk Factors
Risk Factors 16 Special Note Regarding Forward-Looking Statements 57
Use of Proceeds
Use of Proceeds 59 Market Information for Common Stock and Dividend Policy 60 Capitalization 61
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 63
Business
Business 82 Management 101 Executive and Director Compensation 107 Certain Relationships and Related Party Transactions 115 Principal Stockholders 118 Material U.S. Federal Income Tax Consequences 120
Description of Capital Stock
Description of Capital Stock 128
Description of Securities We are Offering
Description of Securities We are Offering 130 Plan of Distribution 136 Legal Matters 139 Experts 139 Where You Can Find Additional Information 139 Index to Financial Statements F-1 5 Table of Contents ABOUT THIS PROSPECTUS The registration statement we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC before making your investment decision. You should rely only on the information provided in this prospectus. You should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document, even though this prospectus or any related free writing prospectus is delivered, or securities are sold, on a later date. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed as exhibits to the registration statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the heading "Where You Can Find More Information." You should rely only on the information that we have included in this prospectus and any related free writing prospectus that we may authorize to be provided to you. Neither we, nor the placement agent, have authorized any dealer, salesman or other person to give any information or to make any representation other than those contained in this prospectus or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained in t